Novartis new data reinforces superiority of Cosentyx® versus Stelara®
Novartis announced results from the head-to-head CLARITY study demonstrating superiority of Cosentyx® (secukinumab) compared to Stelara® (ustekinumab) in delivering clear and almost clear skin in adults with moderate-to-severe plaque psoriasis at 12 weeks. January 16, 2018